A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
200
Specified dose on specified days
Specified dose on specified days
Local Institution - 0144
Mean change from baseline in Hamilton Depression Rating Scale -17 Item (HDRS-17) total score
Time frame: Up to Day 57
Number of Participants with Treatment Emergent Adverse Events (AEs)
Time frame: Up to 71 days
Number of Participants with Serious Adverse Events (SAEs)
Time frame: Up to 71 days
Number of Participants with AEs Leading to Treatment Discontinuation
Time frame: Up to 71 days
Number of Participants with AEs Leading to Death
Time frame: Up to Day 71
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Phoenix, Arizona, United States
Local Institution - 0038
Little Rock, Arkansas, United States
Local Institution - 0047
Rogers, Arkansas, United States
Local Institution - 0046
Garden Grove, California, United States
Local Institution - 0042
Glendale, California, United States
Local Institution - 0071
Lemon Grove, California, United States
Local Institution - 0079
Oakland, California, United States
Local Institution - 0050
Upland, California, United States
Local Institution - 0007
Jacksonville, Florida, United States
Local Institution - 0024
Orlando, Florida, United States
...and 17 more locations